calicheamicin theta(1)I

Detailed behind-the-scenes accounts of the total syntheses of calicheamicin γ(1)(I), Taxol(®), and brevetoxin A are discussed… Expand

Targeting CD33 or CD45 is currently exploited for immunotherapy of acute myeloid leukemia (AML). Gemtuzumab ozogamicin (GO), an… Expand

Gemtuzumab ozogamicin (GO) contains an anti-CD33 antibody to facilitate uptake of a toxic calicheamicin-gamma(1) derivative… Expand

Cells, which lacked the activity of the nuclease Artemis, retained approximately 10% of unrepaired double strand breaks (DSBs) at… Expand

Gemtuzumab ozogamicin (GO; Mylotarg), a novel immunoconjugate used for treatment of acute myeloid leukemia (AML), contains the… Expand

Calicheamicin ϑII is a member of the enediyne class of antitumor antibiotics that bind to DNA and induce apoptosis. These… Expand

It is assumed that the efficient antitumor activity of calicheamicin gamma1 is mediated by its ability to introduce DNA double… Expand

The anti-CD33 antibody, P67.6, has been chosen to target the potently cytotoxic calicheamicin antitumor antibiotics to acute… Expand

In search for a new therapeutic approach for metastasized renal cell carcinoma (RCC), we evaluated the cytotoxicity of a novel… Expand

The suppression of metastases in malignant diseases is one of the major goals in targeted chemotherapy. This was achieved with an… Expand